Expertise in
28
conditions

Dr. Danko Martincic

Oncology
Optum Idaho-Panacea Oncology
1641 E Polston Ave Ste 102, 
Post Falls, ID 
Offers Telehealth
Expertise in
28
conditions
Optum Idaho-Panacea Oncology
1641 E Polston Ave Ste 102, 
Post Falls, ID 

Overview

Danko Martincic is an Oncologist practicing medicine in Post Falls, Idaho.

Dr. Martincic is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Familial Colorectal Cancer, Lung Cancer, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 5 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in ID

Hospital Affiliations

Northwest Specialty Hospital
Shoshone Medical Center
Bonner General Hospital
Kootenai Health
Benewah Community Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PacificSource
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Optum Idaho-Panacea Oncology
1641 E Polston Ave Ste 102, Post Falls, ID 83854
Other Locations
Office
3815 N Schreiber Way Unit 101, Coeur D Alene, ID 83815

Additional Areas of Focus

Dr. Martincic has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
Study Phase: Phase 2
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: July 31, 2017
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

3 Total Publications

Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a surveillance, epidemiology, and end results (SEER) analysis.
Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a surveillance, epidemiology, and end results (SEER) analysis.
Journal: American journal of clinical oncology
Published: July 12, 2012
Similar Doctors
Expertise in
59
conditions
Expertise in
59
conditions
Referral may be required

Kootenai Clinic Cancer Services Pharmacy

1440 E Mullan Ave, 
Post Falls, ID 
 (6.4 miles away)
208-625-4700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kevin Mulvey is an Oncologist practicing medicine in Post Falls, Idaho. Dr. Mulvey is highly rated in 59 conditions, according to our data. His clinical expertise encompasses Follicular Lymphoma, Large-Cell Immunoblastic Lymphoma, Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration.

Expertise in
38
conditions
Expertise in
38
conditions
Referral may be required

Office

3815 N Schreiber Way Unit 101, 
Coeur D Alene, ID 
 (0.1 miles away)
208-755-2804
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Bartels is an Oncologist practicing medicine in Coeur D Alene, Idaho. Dr. Bartels is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Malignant Peripheral Nerve Sheath Tumor, Familial Colorectal Cancer, Paget Disease of the Breast, and Colorectal Cancer.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required
Before you request
1204 North Vercler Road, 
Spokane Valley, WA 
 (20.0 miles away)
509-228-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kristine Rinn is an Oncologist practicing medicine in Spokane Valley, Washington. Dr. Rinn is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Rinn is currently accepting new patients.

Frequently Asked Questions about Dr. Danko Martincic

How do I make an appointment with Dr. Danko Martincic?

You can book an appointment with Dr. Danko Martincic by calling their office at 208-755-2804. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Danko Martincic a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Danko Martincic is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Danko Martincic specialize in?

While Dr. Danko Martincic is a Oncology, they have specific expertise in Multiple Myeloma, Familial Colorectal Cancer, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Danko Martincic participate in research or clinical trials?

Yes. Dr. Danko Martincic has published 3 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Danko Martincic's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Danko Martincic accept my insurance?

Dr. Danko Martincic accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 208-755-2804 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Martincic's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 21 Advanced Conditions
    View All 91 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile